Abstract

Plasma medicine is an emerging novel therapeutic field. It has been reported that plasma can kill bacteria, promote wound healing and induce apoptosis of tumor cells. However, the effects of plasma on immune cells and immune related skin diseases have not been well studied. In this study, we demonstrated that non-thermal atmospheric plasma (NTP) treatment could inhibit psoriasis-like skin inflammation in mice. NTP treatment in imiquimod-induced psoriasis-like mouse skin inhibited increases in epithelial cell thickness and expression of pro-inflammatory molecules compared to ones without the NTP treatment. In addition, differentiation of Th17 cells, an important cell type for pathogenesis of psoriasis, was inhibited in the NTP-treated mouse lymph nodes. It was also demonstrated that liquid type plasma (LTP), which is also known as indirect plasma, inhibited Th17 cell differentiation in vitro. Other in vitro experiments showed that LTP inhibited bone marrow-derived dendritic cell activation. Interestingly, LTP enhanced PD-L1 expression in HaCaT cells, suggesting that NTP may inhibit unwanted over-activation of T cells through increased PD-L1 expression. Taken together, these results suggest that NTP may be used in treatment of CD4+ T cell-mediated autoimmune diseases such as psoriasis.

Highlights

  • Psoriasis is a chronic inflammatory skin disorder, and its histological characteristics are epidermal hyperplasia, increased angiogenesis and immune cell infiltration[1,2]

  • The first clinical trial in patients for non-thermal plasma (NTP) was investigated in Germany in 2010 to reduce bacteria load on chronic wounds because NTP has an ability to kill bacteria, and chronic wounds are infected with bacterial pathogens, which results in the inhibition of the wound healing process[31]

  • Our study demonstrated that NTP treatment could inhibit psoriasis-like skin inflammation through suppression of immune responses using mouse model of psoriasis

Read more

Summary

Introduction

Psoriasis is a chronic inflammatory skin disorder, and its histological characteristics are epidermal hyperplasia, increased angiogenesis and immune cell infiltration[1,2]. Anti-IL-17 antibody, anti-PD-1 antibody and/or recombinant PD-L1 therapies for psoriasis treatment might be used to treat other autoimmune diseases[20] These therapies could cause risk of infections or cancers because the therapies inhibit hosts’ defense immune systems. We investigated whether NTP treatment can inhibit imiquimod-induced psoriasis-like skin inflammation in mice. Our results showed that NTP treatment can treat psoriasis-like skin inflammation through inhibition of CD4+ T cell differentiation, suppressed pro-inflammatory responses, and induction of PD-L1 expression. These results imply that NTP can be used for the treatment of immune-related inflammatory skin diseases

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call